Hormone Replacement Therapy for Breast Cancer
Author Information
Author(s): MER O'Brien, A Montes, TJ Powles
Primary Institution: Royal Marsden Hospital
Hypothesis
Can Org OD 14 (tibilone) be an effective treatment for post-menopausal women with advanced breast cancer who have failed tamoxifen therapy?
Conclusion
The study found that Org OD 14 showed limited effectiveness, with only one patient responding to treatment.
Supporting Evidence
- One patient had a partial response lasting over 6 months.
- Vaginal bleeding occurred in four patients, indicating significant toxicity.
- All patients stopped treatment due to progressive disease.
Takeaway
This study tested a new drug for women with breast cancer who didn't respond to another treatment, but it only helped one person.
Methodology
This was a phase II study involving 14 post-menopausal women with advanced breast cancer who had previously failed tamoxifen treatment.
Limitations
The study had a small sample size and observed significant toxicity, including vaginal bleeding.
Participant Demographics
All participants were post-menopausal women with a median age of 63 years.
Want to read the original?
Access the complete publication on the publisher's website